Thermo Fisher Scientific, the global leader in serving science, has officially opened its new Cell and Gene Therapy (CGT) Vision Centre in South Korea, expanding its worldwide network dedicated to advancing next-generation therapeutic development. The state-of-the-art facility aims to accelerate breakthroughs in personalized medicine by providing comprehensive support across the entire cell and gene therapy value chain.
The strategic investment comes as South Korea's cell and gene therapy market demonstrates significant growth potential. According to market reports, the sector is expected to reach $1.067 billion by 2027, growing at a compound annual growth rate (CAGR) of 16.9% from $0.489 billion in 2023. Over the past five years, the market has already recorded an impressive CAGR of 21.2%, reaching $0.403 billion in 2022.
Comprehensive Support Across the Therapy Development Pipeline
The CGT Vision Centre is specifically designed to empower biopharmaceutical companies with end-to-end solutions spanning from early-stage discovery through clinical development and commercial manufacturing. This integrated approach addresses the complex challenges associated with developing and scaling advanced therapies.
"The CGT field is driving breakthroughs in treating rare and intractable diseases, advancing personalized medicine, and shaping the future of regenerative medicine," said Soo Jin Seok, General Manager at Thermo Fisher Scientific Korea. "These innovations require highly specialized support from discovery through commercialization. With the launch of the CGT Vision Centre, we will empower our customers with access to cutting-edge technologies, regulatory expertise, and end-to-end workflow solutions—strengthening their ability to innovate and scale."
Regional Hub for Innovation and Collaboration
The new facility will serve as a regional hub for cell and gene therapy development in Asia, offering specialized services that include hands-on training, process optimization support, and collaboration opportunities. These capabilities are designed to help accelerate the delivery of life-changing therapies to patients with rare and difficult-to-treat conditions.
The centre represents Thermo Fisher's continued commitment to advancing scientific innovation in Asia while reinforcing its leadership position in providing cell and gene therapy solutions globally. By establishing this specialized facility in South Korea, Thermo Fisher is strategically positioning itself within one of the region's fastest-growing markets for advanced therapeutics.
Meeting the Growing Demand for Advanced Therapeutic Solutions
As cell and gene therapies continue to revolutionize treatment approaches for previously untreatable conditions, the demand for specialized development and manufacturing capabilities has increased substantially. The CGT Vision Centre addresses this need by providing access to Thermo Fisher's extensive portfolio of technologies and expertise.
The facility will enable local biopharmaceutical companies and research institutions to leverage world-class resources without the need for extensive international collaboration, potentially accelerating development timelines and reducing costs associated with bringing these complex therapies to market.
This expansion aligns with Thermo Fisher's broader strategy of establishing regional centers of excellence to support the growing global cell and gene therapy sector, which has seen remarkable clinical successes and increasing investment in recent years.
